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with a more advanced chondrocyte-like phenotype as can found in the
growth plate. We additionally demonstrated that in mesenchymal
stem cells TGF-beta could induce chondrogenesis when BMP activity
was inhibited but not vice versa. This suggested that BMP2 requires an
alternative trigger, like TGF-beta, to induce the initiation of chondro-
genesis. We wanted to know whether this observation could be
extrapolated to osteophyte formation during experimental OA: Can
BMP2 induce osteophyte formation in experimental OAwhen TGF-beta
activity is blocked.
Methods: We made a unique transgenic mouse which expresses BMP2
under control of the Col2a1 promoter but only when exposed to
doxycycline (Col2a1-rtTA-BMP2). As a result, chondrocytes start to
produce BMP2 when this unique transgenic mouse is exposed to
doxycycline. We exposed these mice to doxycycline in food up to 8
weeks to investigate osteophyte formation in knee joints using his-
tology. In addition, we induced osteoarthritis by destabilization of the
medial meniscus (DMM-model), which amongst others results in
osteophyte formation, and investigated whether BMP2 augmented
osteophyte formation. Moreover, to investigate whether TGF-beta was
required for BMP2-related osteophyte formation we combined the
DMM-model with intra-articular injection of an adenovirus over-
expressing the speciﬁc TGF-beta inhibitor LAP with our without dox-
ycycline to overexpress BMP2. Murine knee joints were isolated 4
weeks after DMM exposure for histology to investigate effects on
osteophyte formation.
Results: Four out of 10 dox-treated Col2a1-rtTA-BMP2 mice had more
osteophytes than controls, but dox versus non-dox treated groups
were not signiﬁcantly different. When OA was induced, clearly
osteophytes developed with an average of 4.25 osteophytes per knee
joint. However, when these mice were treated with dox, thus induc-
ing chondrocyte-speciﬁc BMP2 expression in addition to OA, we
found a signiﬁcant increase in the number of osteophytes (8.0)
compared to DMM non-dox (Figure A, B). These “new” osteophytes
were much Iarger than regular DMM-induced osteophytes
(Figure A,C). The lack of osteophytes when treated with dox alone
compared to DMM with dox implied that the DMM treatment pro-
vided a trigger crucial for BMP2 to be able to aggravate osteophyte
formation. To investigate whether TGF-beta was that trigger we
inhibited TGF-beta inhibition by i.a. injection of Ad-LAP one day after
DMM-induction. This showed that without TGF-beta, BMP2 was no
longer capable of augmenting the number of osteophytes duringDMM as there were no signiﬁcant differences in osteophyte number
comparing DMM-Ad-LAP treated animals with or without dox
(Figure B,C). When focusing on the osteophytes that regularly develop
during DMM originating from the periost on the medial side of the
joint,we found an additional striking ﬁnding: the inhibition of TGF-
beta early during OA signiﬁcantly reduced the speed of osteophyte
formation which therefore were still in a chondrophyte at the
moment of sacriﬁce of the mice. This effect was completely abolished
by the additional presence of BMP2 which restored the osteophyte
maturation from chondrophyte to osteophyte.
Conclusions: Our data show that BMP2 is capable of inducing osteo-
phyte formation, but is dependent on an additional prior trigger to
achieve this, as present in OA. In OA conditions, BMP2 can severely
aggravate osteophyte formation, both in number and size. However,
when TGF-beta is blocked BMP2 is no longer capable of aggravating
osteophyte formation during DMM. Strikingly, early inhibition of TGF-
beta during OA impaired the speed of osteophyte formation, which
could be compensated by the presence of BMP2. Our data show for the
ﬁrst time that BMP2 is dependent on TGF-beta to induce de novo
osteophyte formation. This provides novel insight into the mechanism
behind osteophyte formation and provides clues for future therapeutic
application for osteophyte formation in OA.
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Background: The goal of this study is to understand role of trans-
forming growth factor beta 1 (TGF-b1) in development of osteoarthritis
(OA). Results from studies indicate that the genetic inactivation of
Smad-3, or the disruption of the interaction of Tgf-b1 with its receptor
Tgf-b type II receptor (Tgfbr2), in germline cells results in OA-like knee
joints in mice at one month of age. However, other studies suggest that
the increased expression of Tgf-b1 in mature knee joints causes early
onset OA in animal models. Interestingly, a human genetic study reports
that a two-nucleotide deletion, 741-742del AT (nonsense mutation), in
SMAD-3 causes early-onset OA in one family. This human genetic study
also reports that a nucleotide change, 859C>T or 782C>T, in SMAD-3
increases the level of TGF-b1 and activity of the TGF-b1 signaling in two
families associated with early-onset OA. The observation in these
human families is consistent with the results from the animal models,
indicating that the lack of Tgf-b1 signaling in the germline cell results in
OA in developing joints and that increased Tgf-b1 signaling causes OA in
mature joints. The plausible explanation for this “conﬂicting” role of
TGF-b1 in the pathogenesis of OA is: effective TGF-b1 signaling acts in a
dose-dependent manner or a developmental stage-dependent manner.
The present study addresses the question as to whether inhibition of
Tgf-b1 signaling prevents mature knee joints from being degenerated in
mouse models of OA.
Method: 1) By use of conditional knock out techniques with aggrecan-
CreERt2 mice and ﬂoxed Tgfbr2 mice, Tgfbr2 was removed from artic-
ular cartilage of knee joints in mice at two months of age. Mice without
Tgfbr2 were kept for another 6 months or longer. Knee joints from the
mice (n¼4) and their corresponding control (n¼4) were then collected
for morphological analysis. 2) Type XI collagen-haploinsufﬁciency
(Col11a1þ/-) mice, a spontaneous mouse model of OA, were treated
with a neutralizing TGF-b1 antibody (25 mg) by intra-articular injection
into the knee joints at 2 months of age. An additional injection was
performed 2 weeks after the ﬁrst injection. Knee joints were collected
from mice at 6 months (n¼4) and control mice (n¼4) after the second
injection for morphological analysis. 3) Mice were subjected to desta-
bilization of the medial meniscus (DMM) or sham surgery. Immediately
following the surgery, the mice were treated with Losartan orally (0.6g/
1L drinking water) for 4 weeks (other studies indicate that Losartan
reduces the expression of Tgfbr2). The average intake of Losartan was
about 2.5mg/10g mouse body weight/day. Mice without the treatment
of Losartan served as controls. Mice were sacriﬁced at 8 weeks (n¼6)
following the surgery for collection of knee joints. 4) Mice without
Tgfbr2 at two months of age were subjected to DMM to induce articular
Figure 1. OP1 activates canonical (P-Smad 1/5/8 signaling in A) healthy
and B) OA meniscus cells. C) P-Smad 1/5/8 densitometry, normalized to b-
actin, relative to unstimulated controls (mean þ/- SD).
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surgery (n¼4 in each group) were collected for morphological analysis.
Results: 1) We did not ﬁnd the initiation and acceleration of articular
cartilage degeneration by the genetic inactivation of Tgfbr2 in knee
joints of mice at the age of 9 months or older. We also did not ﬁnd
hypertrophic chondrocytes in the articular cartilage of the mice. 2) We
found that intra-articular injection of neutralizing TGF-b1 antibody into
the knee joints of Col11a1þ/- mice delayed articular cartilage degen-
eration approximately 3 months, compared to that in Col11a1þ/- mice
without the injection of the antibody. It takes about 15 months for
Col11a1þ/- mice to form OA knee joints. 3) We found that treatment
with Losartan delayed articular cartilage degeneration, induced by
DMM, compared to that in control littermates. 4) We found that
removal of Tgfbr2 in articular cartilage of knee joints delayed articular
cartilage degeneration, induced by DMM, at least 6 weeks, compared to
that in wild-type littermates. It takes about 16 weeks for mice with
DMM to develop OA knee joints.
Conclusion: Inhibition of Tgf-b1 signaling attenuated articular cartilage
degeneration in mature knee joints of mouse models of OA. Therefore,
inhibition activity of TGF-b1, not application of TGF-b1, may be con-
sidered in treatment of OA in mature joints.
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Purpose: Degenerative meniscus injuries are highly prevalent in aged
individuals, increasing the risk and rate of total joint OA onset. Ideally,
therapies should incite anabolic matrix production and prevent total
joint tissue OA progression. However, anabolic resistance occurs during
articular cartilage aging and OA. It is thought to contribute to the risk of
OA progression due to insufﬁcient repair of normal tissue microtrauma.
Anabolic insensitivity also contributes to net tissue breakdown during
OA due to decreased tissue synthesis. Mechanisms of anabolic insen-
sitivity have not been described for meniscus tissue. The objective of
this study was to characterize normal and OA meniscus cell response to
the anabolic growth factor, Osteogenic Protein 1 (OP1/BMP7), and
examine mechanisms of anabolic resistance to OP1 during OA.
Methods: Normal human tissue was obtained through NDRI or Gift of
Hope Tissue and Organ Donor Network. Osteoarthritic tissues were
obtained as total knee arthroplasty surgical waste under IRB approval.
Normal meniscus was grade 2 or less by ICRS scores. Primary meniscus
cells were grown as high density monolayer cultures, changed to serum
free media upon reaching conﬂuence, and treated with OP1 (100 ng/
mL) or comparisons of IL1b (10 ng/mL), TGFb (10 ng/mL), GDF5 (100 ng/
mL), or IGF1 (100 ng/mL). Expression of ECM components and MMPs
was determined by RT-qPCR. Total lysates were analyzed by immuno-
blotting and evaluated using antibodies against activating phosphor-
ylations or total proteins for Smads (1/5/8, 2), MAPKs (ERK, p38), and
AKT. Band intensity was measured by ImageJ densitometry, normalized
for background and total protein, and expressed relative to unstimu-
lated samples.
Results: By RT-qPCR, OP1 stimulation increased aggrecan and collagen
type II (COL2A1) mRNA and decreased MMP-13 mRNA in all samples,
however OA meniscus cells showed reduced responses compared to
healthy cells. Normal meniscus cells separated from inner and outer
meniscus regions displayed similar mRNA levels upon OP1 stimulation,
suggesting the decreased response of OA cells to OP1 was due to disease
state, not loss of tissue region (data not shown). To identify potential
mechanisms of anabolic insensitivity, we evaluated signaling time
courses by immunoblot. Normal (n¼2) and OA (n¼3) meniscus cells,
stimulated with OP1, displayed activation of canonical BMP signaling,
evidenced by Smad1/5/8 phosphorylation (P-Smad1/5/8), while non-
canonical MAPK or AKT signaling was not observed (Figure 1A&B).
Maximum P-Smad1/5/8 occured at late time points (1.5 hours) with
similar kinetics between normal and OA cells. Normal cells responded
to OP1 stimulation with enhanced levels of P-Smad1/5/8 compared to
OA cells (Figure 1C). Stimulation with IL-1b or IGF1 showed limited
Smad 1/5/8 activation, while MAPK or AKT was activated, as expected.
Stimulation with TFGb resulted in both enhanced phospho-Smad 2 and
Smad 1/5/8 in normal and OA cells compared to unstimulated controls.
TFGb treatment induced higher phospho-Smad 1/5/8 levels in normal
vs. OA meniscus cells, similar to OP1 treated cells.Conclusions: OA meniscus cells are resistant to OP1 stimulated
extracellular matrix transcription compared to normal meniscus cells.
MMP expression is not induced by either normal or OA meniscus cells,
indicating that OP1 is not harmful and has potential therapeutic beneﬁt
for OA meniscus. Both normal and OA meniscus cells respond to OP1
stimulation by activating canonical BMP signaling (Smad1/5/8), but not
non-canonical signaling. Our current signaling experiments using OP1
and including TFGb suggest that meniscus anabolic resistance does not
affect kinetics of Smad activation, but inﬂuences total amount of Smad
phosphorylation. Stimulation with TFGb also resulted in differential
Smad 1/5/8 activation, suggesting that Smad signaling is a target
pathway for overcoming anabolic resistance during meniscus cell OA.
Discovering mechanisms of OA cell anabolic resistance will enhance
therapeutic targeting to overcome resistance and contribute to resto-
ration of tissue homeostasis beneﬁcial to the whole knee joint.23
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Purpose: Despite the advantages in the ﬁeld of regenerative medicine
for cartilage repair, the research of available and effective treatments for
osteoarthritis (OA) represents a major challenge for clinicians. To this
regard, the use of bone marrow concentrate (BMC), containing different
cell populations including Mesenchymal Stromal Cells (MSCs) sur-
rounded by their microenvironment with a cocktail of multiple growth
factors, could represent a novel therapeutic approach for OA manage-
ment. This methodology allows to perform a one -step procedure
through a density gradient centrifugation of autologous bone marrow
avoiding all the problems related to cell manipulation. Most recent
studies demonstrated beneﬁts of the use of BMC for osteochondral
reconstruction in critical-sized defects.The purpose of this study was,
therefore, to assess the efﬁcacy of the use of BMC seeded onto a hya-
luronan scaffold compared to the use of expanded isolated MSCs in a
sheep model of OA.
Methods: Skeletally mature female Merino sheep were used for this
study.The induction of OAwas done surgically through unilateral partial
medial meniscectomy (MMX) to achieve amild grade of OA at 12weeks.
Treatment approaches consisted of autologous BMC and/or MSC seeded
onto Hyaff-11 from bone marrow and transplanted into the knee joint;
no treatment (OA group) and empty Hyaff-11 were used as controls.
Cartilage from femoral condyle and tibial plateau, synovial membranes
and medial menisci were assessed by macroscopic and histological
analysis supplemented by speciﬁc scoring systems. Protein expression
of various ﬁbrous, cartilaginous, catabolic, hypertrophic and inﬂam-
matory markers were examined by immunohistochemistry. All the
assessments were carried out 3 months after implantation. Data were
reported using 95% conﬁdence of interval of the mean and/or mean
with standard deviation.
Results: A mild grade of OA was developed after MMX at 12 weeks. A
series of OA changes, including cartilage loss, cell clones, hypertrophic
processes, subchondral bone thickness, osteophytes, hyperplasia of
